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The aim of this study was to assess the effect of artichoke (Cynara scolymus) leaf aqueous extract 
(ALE) on streptozotocin (STZ)-induced diabetic rats. ALE (200 and 400 mg/kg body weight) was 
administered to STZ-induced diabetic rats and fasting blood glucose, total cholesterol (TC), triglyceride 
(TG), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), 
atherogenic index, lipid peroxidation (LPO), red blood cell (RBC) superoxide dismutase (SOD) activity 
and plasma antioxidant capacity were measured. The oral administration of ALE for 21 days 
significantly reduced TC, TG, LDL-C, VLDL-C and hyperglycemia in treated diabetic rats as compared to 
diabetic control group. ALE also markedly ameliorated the level of plasma malondialdehyde (MDA) and 
increased plasma antioxidant capacity of treated diabetic group. The results clearly indicate the 
beneficial reducing effects of ALE on serum TC, TG, LDL-C, VLDL-C, glucose levels and plasma MDA 
level in STZ-treated rats. 
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INTRODUCTION  
 
Diabetes mellitus (DM) is a chronic disease characterized 
by disorders in metabolism of carbohydrates, lipids and 
several essential trace elements (Kazi et al., 2008). The 
use of lipid lowering diets and drugs are common for 
treating of hyperlipidemia in diabetes (Moon and 
Kashyap, 2004). Since, herbal drugs are generally out of 
toxic effect, using traditional and complementary 
medicine is developing for treatment of different diseases 
(Kameswara et al., 2003). Several reported studies 
screened some plants having folk medicine reputation for 
antidiabetic potency (Gupta et al., 2004; Vats et al., 2002) 
but there was no scientific publication about the artichoke  
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on STZ-induced diabetic rats. 
Medicinal plants especially artichoke (Cynara scolymus 
L.) leaves have long been used effectively for treating a 
variety of diseases in the world. Artichoke is full of natural 
antioxidants and contains caffeoylquinic acid derivatives 
(cynarin and chlorogenic acids) and flavonoids such as 
luteolin and apigenin (Llorach et al., 2002; Wang et al., 
2003). Artichoke has been reported to significantly 
reduce serum cholesterol in hypercholesterolemic 
subjects (Joy and Haber, 2007) and declined the 
production of reactive oxygen species (ROS), lipid 
peroxidation and the oxidation of low-density lipoproteins 
in vitro experiments (Zapolska-Downar et al., 2002). 
There are few reports on anti-diabetic activity of C. 
scolymus. Therefore, this study was an attempt to assess 
the effect of C. scolymus aqueous extract on some 
biochemical factors such as lipid profiles and LPO, serum  
glucose,  HbA1c,  SOD  activity  of  RBC, and antioxidant 
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capacity in STZ-induced diabetic rats.  
 
 
MATERIALS AND METHODS 
 
Chemicals 
 
Streptozotocin (STZ) and 2, 4, 6-tripyridyl-s-triazine (TPTZ) were 
obtained from Sigma (Sigma Chemical Co., USA). superoxide 
dismutase (SOD) linked immunosorbant assay (ELISA) kit 
purchased from Cayman Chemical Co. (U.S.A), Hb A1c kit 
purchased from Biosystem Co. (Spain), 2-thiobarbituric acid (TBA), 
ferric chloride, ethylenediaminetetra acetic acid (EDTA), sodium 
dodecyl sulfate (SDS) obtained from Merck (Germany). All the other 
chemicals used were of analytical grade. 
 
 
Preparation of artichoke leaf aqueous extract  
 
The artichoke used in our study was obtained from Isfahan 
Agricultural Research Center (Iran). The artichoke leaf extract 
(ALE) was prepared by adding 1000 ml of distilled water to 100 g of 
leaf powder and kept at 60°C for 60 min. The aqueous extracts 
were filtered and the filtrate was evaporated to dryness at 50°C. 
The residue was stored at 0 to 4°C for subsequent experiments. 
The fraction was dissolved in distilled water just prior to 
experimentation. 
 
 
Induction of diabetes  
 
Male Wistar rats, 200 to 250 g, were used for this experiment and 
kept in cages under standard laboratory conditions (12 h light/12 h 
darkness, 21 ± 2°C). Diabetes was induced by a single 
intraperitoneal injection (i.p) of freshly prepared STZ (60 mg/kg 
body weight) in ice-cold physiological saline (Bagri et al., 2009). 
The animals were considered diabetic, if their blood glucose values 
were above 300 mg/dl on the 5th day of STZ injection and 
accompanied by polydipsia and polyuria (Bagri et al., 2009; Baydas 
et al., 2003). The animals were given standard pellets diet and 
water ad libitum throughout the experimental period. 
 
 
Experimental design and administration of ALE 
 
The rats were randomly divided into 4 groups (n= 6/ group) as 
follows. The artichoke leaf extract (200 and 400 mg/kg) were 
administered orally via gavage in aqueous solution once per day. 
 
Group I: Normal control rats, received ice-cold physiological saline 
(1 ml/kg, body weight). 
Group II: Diabetic control rats, received STZ in single dose (60 
mg/kg, body weight). 
Group III: ALE treated diabetic rats, received ALE (200 mg/kg/day, 
p.o.) 5 days after STZ treatment for 21 days.  
Group IV: ALE treated diabetic rats, received ALE (400 mg/kg/day, 
p.o.) 5 days after STZ treatment for 21 days. 
 
After 21 days of the administration period, blood samples were 
obtained through cardiac puncture for biochemical estimations, and 
then the serum and plasma were immediately separated from the 
blood samples by centrifugation. All animal procedures were 
performed with regard to Iranian animal ethics society and local 
university rules.  
 
 
 
 
Analytical procedures 
 
Serum TC, TG and HDL-C were determined by enzymatic method  
(Pars Azmun kit, Iran) with JENWAY spectrophotometer (model 
6105, England). LDL-C and VLDL-C were calculated with Fridewald 
formula (Friedewald et al., 1972). The plasma MDA level was 
measured as LPO by the thiobarbituric acid reactive substances 
(TBARS) method described by Ohkawa et al. (1979). Briefly, to 100 
µl plasma or standard, 100 µl sodium dodecyl sulfate (8.1%) and 
2.5 ml TBA/buffer (prepared by dissolving of 0.53% thiobarbituric 
acid in 20% acetic acid as adjusted to pH 3.5 with NaOH) were 
added. The tubes were covered with caps and incubated at 95°C 
for 60 min. The reaction was stopped by placing tubes on ice 
followed by centrifugation at 4000 rpm for 10 min. The optical 
density of pink color developed in the supernatant was measured 
against distilled water as blank at 532 nm by JENWAY 
spectrophotometer (model 6105, England).  
The measurements were done in duplicates and the results were 
expressed in µmol/L. MDA standards were prepared from 1, 1, 3, 3-
tetraethoxypropane. Antioxidant power of plasma was determined 
by measuring its ability to reduce Fe3+ to Fe2+ with ferric reducing 
ability of plasma (FRAP) test (Benzie and Strain, 1996). The 
reagents included 300 mM acetate buffer (3.1 g of sodium acetate 
3H2O + 16 ml of glacial acetic acid made up to 1 L with distilled 
H2O, pH=3.6), 10 mM TPTZ (trypyridyl-s-triazine) in 40 mM HCl and 
a 20 mM FeCl3. Fresh working FRAP reagent was provided by 
mixing 25 ml acetate buffer, 2.5 ml TPTZ solution and 2.5 ml FeCl3. 
Fifty five microliter of plasma was added to 1.5 ml of freshly 
prepared working FRAP reagent and incubated at 37°C. After 10 
min, the complex between Fe2+ and TPTZ gives a blue color with 
absorbance at 593 nm. FeSO4 was used as a standard of FRAP 
assay at a concentration range between 100 and 1000 µM. The 
results are expressed as µmol/L. SOD of RBC was measured by 
ELISA kit (Cayman Chemical Co. U.S.A) with Kayto microplate 
reader (model RT 21000, China), in accordance with the 
instructions of the manufacture. HbA1c was determined by 
Biosystem kit (Spain), in accordance with the instructions of the 
manufacturer.  
 
  
Statistical analysis  
 
Data were expressed as mean ± SD. The data were analyzed by 
SPSS software (version 11.5). For statistical analysis of the data, 
group means were compared by one-way analysis of variance 
(ANOVA) followed by LSD post hoc test for multiple comparison. 
Differences were considered significant at P < 0.05 level. 
 
  
RESULTS 
 
Effect of ALE on hyperglycemia 
 
Figure 1 shows the levels of glucose in normal and 
diabetic animals at the end of the experiment. There was 
a significant elevation (P < 0.001) in serum glucose level 
of the STZ-induced diabetic rats (Group II) when 
compared with normal control rats (Group I). The 
administration of ALE significantly (P < 0.001) decreased 
glucose level in treated diabetic rats (Groups III and IV) 
as compared with diabetic control rats (Group II). Thus, 
the level of blood glucose returned to near normal range 
in treated diabetic rats (Groups III and IV).  
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Figure 1. Effect of ALE on serum glucose in diabetic rats. (I) Normal control; (II) 
diabetic control; (III) ALE treated at 200 mg/kg/body; (IV) ALE treated at 400 
mg/kg/body. The data are expressed as mean ± S.D. (n = 6). *P < 0.001 
compared with the corresponding value for normal control animals. **P < 0.001 
compared with the corresponding value for diabetic control animals. 
 
 
 
Effect of ALE on hyperlipidemia 
 
Table 1 shows the serum levels of TC, TG, LDL-C, VLDL- 
C, HDL-C and atherogenic index (TC/HDL-C, LDL/HDL-
C) in normal and experimental animals in each group. In 
STZ-induced diabetic rats the serum levels of TC, TG, 
LDL-C, VLDL-C were significantly increased (P < 0.001) 
whereas, there was a reduction in HDL-C levels as 
compared to the normal control rats. Also, there was a 
significant (P < 0.001) reduction in TC, TG, LDL-C, VLDL-
C and atherogenic index of diabetic rats treated with ALE 
(Groups III and IV).  
 
 
Effect of ALE on SOD 
 
SOD activity in RBC is shown in Figure 2. There was a 
significant decrease (about 54%, P < 0.001) in SOD 
activity of RBC in STZ-induced diabetic rats compared 
with control rats (Group I). SOD activity was significantly 
increased (P < 0.001) in treated diabetic rats with ALE 
(Groups III and IV) as compared to the diabetic control 
rats (Group II). There was no dose-dependent increase in  
SOD activity following the administration of ALE at 
different concentrations. 
 
 
Effect of ALE on LPO 
 
The levels  of  TBARS  in  blood  plasma  of  the  different  
groups of rats are shown in Figure 3. There was a 
significant (P < 0.001) elevation in TBARS of diabetic rats 
as compared with normal rats. The feeding of diabetic 
rats with ALE (Groups III and IV) for 21 days resulted in 
significant reduction (P < 0.001) in the levels of TBARS in 
plasma, as compared to the diabetic control rats (Group 
II). 
 
 
Effect of ALE on plasma antioxidant power 
 
Plasma antioxidant power significantly declined (P< 0.05) 
in diabetic group in comparison to normal control (Figure 
4). Plasma antioxidant power significantly increased after 
treatment with ALE (P < 0.001) with respect to the 
diabetic control group. The elevation of plasma 
antioxidant power for ALE was not dose dependent. 
 
 
DISCUSSION  
 
In modern medicine insulin therapy is used for the 
management of diabetes mellitus but there are several 
side effects such as insulin resistance, anorexia nervosa, 
brain atrophy and fatty liver (Piedrola et al., 2001; 
Yaryura-Tobias et al., 2001). Also, chronic treatment with 
sulfonylurea and biguanides is associated with some side 
effects (Rang et al., 1991). Therefore, herbal medicine 
development against  the non-communicable disease like
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Figure 2. Effect of ALE on SOD activity in diabetic rats. (I) Normal 
control; (II) diabetic control; (III) ALE treated at 200 mg/kg/body; 
(IV) ALE treated at 400 mg/kg/body. The data are expressed as 
mean ± S.D. (n = 6). *P < 0.001 compared with the corresponding 
value for normal control animals. **P < 0.001 compared with the 
corresponding value for diabetic control animals. 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
I II III IV
M
al
o
n
di
al
de
hy
de
 
(µm
o
l/L
)
Groups
**
**
*
 
 
Figure 3. Effect of ALE on plasma malondialdehyde level in diabetic rats. 
(I) Normal control; (II) diabetic control; (III) ALE treated at 200 
mg/kg/body; (IV) ALE treated at 400 mg/kg/body. The data are expressed 
as mean ± S.D. (n = 6). *P < 0.001 compared with the corresponding 
value for normal control animals. **P < 0.001 compared with the 
corresponding value for diabetic control animals. 
 
 
 
diabetes is one of the trust areas of research for finding 
natural drugs with hypoglycemic activity. Herbal drugs 
have less toxicity with fewer side effects compared with 
synthetic drugs (Kameswara et al., 2003). In the present 
work, we examined the effects of ALE on serum glucose, 
dyslipidemia, HbA1c, SOD activity of RBC, lipid 
peroxidation   and  antioxidant  capacity  in  STZ-induced  
diabetic rats. 
Our results showed that STZ-treated rats had markedly 
increased serum glucose, triglyceride, and total 
cholesterol levels. Hyperglycemia is considered as the 
pathogenesis of diabetes and diabetic complications 
such as oxidative stress and the formation of advanced 
glycation end products (Rolo and Palmeira, 2006).  
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Figure 4. Effect of ALE on plasma antioxidant power in diabetic rats. 
(I) Normal control; (II) diabetic control; (III) ALE treated at 200 
mg/kg/body; (IV) ALE treated at 400 mg/kg/body. The data are 
expressed as mean ± S.D. (n = 6). *P < 0.001 compared with the 
corresponding value for normal control animals. **P < 0.001 compared 
with the corresponding value for diabetic control animals. 
 
 
 
Table 1. Effect of ALE on TC, TG, LDL-C, HDL-C, VLDL-C and atherogenic index (TC/HDL-C, LDL/HDL-C) in diabetic rats. 
 
Parameters Control Diabetic 
control 
Diabetic + ALE  
(200 mg/kg) 
Diabetic +ALE  
(400 mg/kg) 
TC (mg/dl) 83.27±4.41 123.38±7.99* 85.06±7.20** 77.75±10.21** 
TG (mg/dl) 49.45±4.72  59.78±3.17* 47.66±5.46** 37.60±2.89** 
LDL-C (mg/dl) 28.85±4.62 77.01±8.67* 41.03±4.06** 29.31±9.94** 
HDL-C (mg/dl) 44.53±2.64 34.42±1.72* 36.50±1.11** 40.32±2.06** 
VLDL-C (mg/dl) 9.90±0.94 11.95±0.63* 9.53±1.10** 7.50±0.57** 
TC/HDL-C (units) 1.87±0.14 3.59±0.34* 2.38±0.10** 1.92±0.29** 
LDL/HDL-C (units) 0.82±0.13 2.24±0.33* 1.12±0.08** 0.73±0.27** 
 
* P < 0.001 compared with the corresponding value for control animals. ** P < 0.001 compared with the corresponding value for 
diabetic control animals. The data are expressed in mean ± S.D.; n = 6 in each group. 
 
 
 
Hypertriglyceridemia and hypercholesterolemia are 
associated with abnormalities of lipoprotein levels in the 
blood, and STZ increased the levels of chylomicron, 
VLDL, and LDL in the blood, and decreased the HDL 
level (Gylling et al., 2004). Also, dyslipidemia is one of 
the major cardiovascular risk factors. It has been 
suggested that insulin deficiency in DM is associated with 
a variety of abnormalities in metabolic and regulatory 
processes, which causes the accumulation of lipids such 
as TC and TG in diabetic patients (Goldberg, 1981). As 
shown in Table 1 and Figure 1, the levels of serum 
glucose, total cholesterol and triglycerides in the STZ-
treated rats markedly increased compared to normal 
control rats. However, the elevated serum glucose, 
triglyceride   and   total   cholesterol    levels   significantly 
reduced by the oral administration of artichoke (200 and 
400 mg/kg) in a dose-dependent manner. Moreover, 
LDL-C /HDL-C and TC/HDL-C ratios are markers of 
dyslipidemia and atherogenic ratio (Elisaf et al., 1995). 
This ratio has increased both in STZ-treated rats, and 
after the supplementation of ALE, these ratios 
significantly decreased and resettled towards the control 
level in the serum of treated diabetic rats (Groups III and 
IV). ALE supplementation also resulted in the significant 
attenuation in the level of LDL-C and HDL-C in serum, 
toward the control level which again strengthen the 
hypolipidemic effect of this extract. Other reported 
investigations are consistent with our results (Nazni et al., 
2006).  
ALE  contains bioactive and flavonoid compounds such  
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as caffeoylquinic acids and luteolin glucosides. As it is 
known, cynarin is a major dicaffeoylquinic acid and 
chlorogenic acid is the main monocaffeoylquinic acid, 
whereas luteolin-7-O glucoside is the major flavonoid 
(Llorach et al., 2002; Wang et al., 2003). Both 
caffeoylquinic acids and flavonoids present in ALE are 
considered to be responsible for its antiatherogenic 
actions (Gebhardt, 1997; Llorach et al., 2002; Pittler et 
al., 2002; Wang et al., 2003). Also, luteolin is thought to 
be one of the constituents of ALE which inhibits de novo 
synthesis of cholesterol (Gebhardt, 2002). Therefore, in 
the current study the reduction of atherogenic parameter, 
triglyceride and total cholesterol levels in treated groups 
with ALE are due to bioactive and flavonoid compounds 
of ALE. These results indicate that ALE has a lipid-
lowering effect on the diabetic rats.  
Lipid peroxide is considered as cellular injury in 
humans, and is used an indicator of oxidative stress in 
cells and tissues. MDA, lipid peroxide derived from 
polyunsaturated fatty acids, is used as an indicator of 
oxidative stress and lipid peroxidation. In diabetes, 
oxidative stress influences important risk factors such as 
lipid and glucose metabolism. Moreover, in diabetes, high 
blood glucose level leads to glucose auto-oxidation and 
increases oxygen free radicals (Yadav et al., 1997). Diet, 
especially fruit and vegetables, plays a critical role as a 
chemopreventive agent against various diseases through 
their biological active substances such as antioxidants 
(Davi et al., 2005; van der Schouw et al., 2005). Figure 3 
shows serum levels of MDA markedly increased in 
diabetic rats, and it was significantly reduced by oral ALE 
administration compared to diabetic rats. Recently, the 
use of the antioxidant therapy has been reported to have 
various medicinal properties, including the prevention and 
the treatment of diabetes and liver diseases (Medina and 
Moreno-Otero, 2005; Ros et al., 2004). ALE is known to 
have antioxidant potential. Many in vitro studies have 
demonstrated that the antioxidant potential of ALE is due 
to radical scavenging and metal ion chelating effect of its 
constituents such as cynarin, chlorogenic acid and 
flavonoids (Brown and Rice-Evans, 1998; Pérez-Garcia 
et al., 2000). 
Also, the results in this study suggest that ALE can 
alleviate oxidative stress under diabetic pathological 
conditions through the inhibition of lipid peroxidation. 
Diabetes is associated with the reduction of antioxidant 
potential and an increase in the formation of free radicals. 
This situation disturbs the normal balance present in cells 
between radical formation and protection against them 
(Naziro and Butterworth, 2005). Therefore, an imbalance 
of oxidant/antioxidant defence systems leads to 
alterations in the activity of antioxidant enzymes such as 
SOD (Maritim et al., 2003). SOD plays a critical role in 
oxygen defence metabolism by converting superoxide to 
hydrogen peroxide (Lin et al., 2005; Vincent et al., 2004). 
Figures 2 and 4 show that red blood cell SOD activity and 
plasma antioxidant power markedly decreased in diabetic 
rats   (Group   II),    whereas    oral    ALE   administration  
 
 
 
 
significantly increased these parameters in treated rats 
(Groups III and IV) with respect to diabetic rats (Group II). 
The decreased natural cellular antioxidant enzyme SOD 
in control diabetic rats may be due to the formation of 
reactive oxygen species (ROS) such as superoxide (O-2 ), 
hydrogen peroxide (H2O2), and hydroxyl radical (OH-) that 
reduce the activity of SOD as reported by other 
investigators (Kaleem et al., 2006; Vincent et al., 2004). 
 
 
Conclusion 
  
The findings of this work shows a number of positive 
effects of ALE on rats with STZ- induced disturbances in 
lipoprotein profile, antioxidant status, and glucose 
tolerance. Therefore, ALE is useful in the control of 
diabetes, abnormalities in lipid profiles and oxidative 
stress by activation of SOD activity.  
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